Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates
Beijing, China, March 25, 2024 –Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and ABL Bio Inc. (“ABL”, KOSDAQ: 298380), a Korean clinical-stage biotechnology company developing novel therapeutics in oncology and CNS diseases, today announced a collaboration to […]
BIO-Europe Spring 2024 | Schedule 1-on-1 Meetings with Biocytogen
Biocytogen’s antibody BD and licensing team is pleased to attend and host 1-on-1 meetings at BIO-Europe Spring, taking place March 18-20, 2024 in Barcelona, Spain. Biocytogen’s antibody therapeutics R&D division, RenBiologics, offers antibody sequence licensing/co-development, and RenMice® fully human antibody/TCR discovery platform licensing opportunities. RenBiologics: Our Fully Human Library. Your Pipeline. Our team of antibody […]
Join us at World ADC London 2024: Mar 13-14
Join us at the World ADC London 2024 conference in London, UK from March 13-14! Our Chief Scientific Officer and Senior Director of New Drug Development, Dr. Benny Yang, will be presenting “RenBiologics is at the forefront of advancing bispecific ADCs and nanobody ADCs” at 12:30 PM on March 13th. Speaker Session Presenter: Dr. Benny […]
Join us at SAPA-GP Annual Conference 2024: Mar 8-9
Join us at the SAPA-GP Annual Conference 2024 in Pennsylvania from March 8-9, 2024! Whether you need humanized models, pharmacology services, or are seeking antibody partnerships, we’d love to connect with you to learn more about your research objectives. Attend the meeting Talk to us The event typically features presentations and panel discussions from […]
Webinar: Translational Animal Models of Atopic Dermatitis (AD) for Preclinical Studies
February 28, 2024
Our webinar “Translational Animal Models of Atopic Dermatitis (AD) for Preclinical Studies” was live at 12PM EDT on March 27, 2024. About the webinar: Atopic Dermatitis is a chronic inflammatory skin condition characterized by redness, cracking, and scaling, often leading to painful sores. While the precise cause of AD remains unclear, a dysfunctional epidermal barrier […]
Biocytogen Symposium 2024: New Targets, New Therapeutics
Thanks to all who joined us at the 2024 Biocytogen Symposium! Your participation made this event a tremendous success. Whether you joined us in person or remotely, your energy and passion sparked some amazing conversations and connections. We look forward to hosting more opportunities to collaborate and continue advancing drug discovery and development together! The Biocytogen Symposium […]
Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement
Beijing, China, February 19, 2024 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc. The agreement provides Gilead access to Biocytogen’s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets […]
Webinar: Preclinical Pharmacology Services to Support Evaluation of Novel Cell & Gene Therapies
January 30, 2024
Our webinar “Preclinical Pharmacology Services to Support Evaluation of Novel Cell & Gene Therapies” was live at 12PM EST on February 28, 2024. About the webinar: Cell and gene therapies aim to treat diseases through the restoration or alteration of certain sets of cells, or by using cells to carry a therapy through the body. […]
Join us at Next-Gen Immuno-Oncology Conference: Feb 8-9
Join us at the MarketsandMarkets Next-Gen Immuno-Oncology Conference in San Diego, CA from February 8-9, 2024! We’re excited to present “BioMice: Preclinical Oncology/Immuno-Oncology Models for Evaluating Novel Therapeutics in Vivo” on February 8th from 2:20 to 3:00 PM PST – you don’t want to miss this session! Whether you need humanized models, pharmacology services, or […]
Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development
Beijing, China – January 23, 2024 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced the launch of a new sub-brand, RenBiologicsTM, to represent the company’s antibody discovery business division. RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully […]
